4.8 Article

Personalized Mapping of Drug Metabolism by the Human Gut Microbiome

Journal

CELL
Volume 181, Issue 7, Pages 1661-+

Publisher

CELL PRESS
DOI: 10.1016/j.cell.2020.05.001

Keywords

-

Funding

  1. Department of Molecular Biology, Princeton University
  2. NIH Director's New Innovator Award [1DP2AI124441]
  3. New Jersey Commission on Cancer Research Pre-doctoral award [DFHS18PPC056]
  4. National Institute of General Medicine Sciences [T32GM007388]
  5. National Science Foundation Graduate Research Fellowship [2017249408]

Ask authors/readers for more resources

The human gut microbiome harbors hundreds of bacterial species with diverse biochemical capabilities. Dozens of drugs have been shown to be metabolized by single isolates from the gut microbiome, but the extent of this phenomenon is rarely explored in the context of microbial communities. Here, we develop a quantitative experimental framework for mapping the ability of the human gut microbiome to metabolize small molecule drugs: Microbiome-Derived Metabolism (MDM)-Screen. Included are a batch culturing system for sustained growth of subject-specific gut microbial communities, an ex vivo drug metabolism screen, and targeted and untargeted functional metagenomic screens to identify microbiome-encoded genes responsible for specific metabolic events. Our framework identifies novel drug-microbiome interactions that vary between individuals and demonstrates how the gut microbiome might be used in drug development and personalized medicine.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available